LifeMD(US:LFMD) GlobeNewswire News Roomยท2025-09-03 15:10Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against LifeMD, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements and financial guidance [4][6]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in LifeMD to contact them directly to discuss their legal options [1][9]. - A federal securities class action has been filed against LifeMD, with a deadline of October 27, 2025, for investors to seek the role of lead plaintiff [4][8]. Group 2: Allegations Against LifeMD - The complaint alleges that LifeMD and its executives materially overstated the company's competitive position and were reckless in raising the 2025 guidance without properly accounting for rising customer acquisition costs [6]. - Specific issues cited include the failure to disclose rising customer acquisition costs in the RexMD segment and costs related to obesity treatment drugs [6]. Group 3: Financial Impact - On August 5, 2025, LifeMD revised its revenue guidance, expecting total revenue in the range of $250 to $255 million, down from a previous estimate of $268 to $275 million [7]. - Following this announcement, LifeMD's stock price dropped by 44.8% on August 6, 2025 [7].